PT  - JOURNAL ARTICLE
AU  - Sumit Randhir Singh
AU  - Michael W Stewart
AU  - Goura Chattannavar
AU  - Mohammed Ashraf
AU  - Ahmed Souka
AU  - Mazen ElDardeery
AU  - Neeraj Wadhwa
AU  - Chintan Sarvaiya
AU  - Ahmad M Mansour
AU  - Ameen Marashi
AU  - Suresh Ramchandani
AU  - Imoro Zeba Braimah
AU  - Mohammad Hossein Jabbarpoor Bonyadi
AU  - Alireza Ramezani
AU  - Masoud Soheilian
AU  - João Rafael de Oliveira Dias
AU  - Gabriel Costa de Andrade
AU  - André Maia
AU  - Eduardo Büchele Rodrigues
AU  - Michel Eid Farah
AU  - Alay Banker
AU  - Jay Chhablani
ED  - ,
TI  - Safety of 5914 intravitreal ziv-aflibercept injections
AID  - 10.1136/bjophthalmol-2018-312453
DP  - 2019 Jun 01
TA  - British Journal of Ophthalmology
PG  - 805--810
VI  - 103
IP  - 6
4099  - http://bjo.bmj.com/content/103/6/805.short
4100  - http://bjo.bmj.com/content/103/6/805.full
SO  - Br J Ophthalmol2019 Jun 01; 103
AB  - Purpose To analyse the pooled safety data of intravitreal ziv-aflibercept (IVZ) therapy for various retinal conditions.Methods This was a retrospective, observational study which included patients from 14 participating centres who received IVZ. The medical records of patients who received IVZ from March 2015 through October 2017 were evaluated. Patient demographics and ocular details were compiled. Ocular and systemic adverse events that occurred within 1 month of IVZ injections were recorded and defined as either procedure-related or drug-related.Results A total of 1704 eyes of 1562 patients received 5914 IVZ injections (mean±SD: 3.73±3.94) during a period of 2.5 years. The age of patients was 60.6±12.8 years (mean±SD) and included diverse chorioretinal pathologies. Both ocular (one case of endophthalmitis, three cases of intraocular inflammation, and one case each of conjunctival thinning/necrosis and scleral nodule) and systemic adverse events (two cases of myocardial infarction, one case of stroke and two deaths) were infrequent.Conclusion This constitutes the largest pooled safety report on IVZ use and includes patients from 14 centres distributed across the globe. It shows that IVZ has an acceptable ocular and systemic safety profile with incidences of adverse events similar to those of other vascular endothelial growth factor inhibitory drugs. The analysis supports the continued use of IVZ in various retinal disorders.